Laboratory (LH) DIvidends Date & History

Key Takeaways

• Labcorp Holdings offers a current dividend yield of 1.09%, paid quarterly at $0.72 per share.
• The payout ratio stands at 27.5%, indicating strong sustainability backed by earnings and free cash flow (FCF, cash generated after capital expenditures).
• No dividend cuts in recent history; payments have remained consistent, though growth has been flat recently.
• Yield trails peer DGX at approximately 1.75% but offers superior payout coverage.
• Upcoming ex-dividend date is May 29, 2026, with payment on June 11, 2026.
• Ideal for conservative investors prioritizing stability over high income.

Dividend Overview

Labcorp Holdings Inc. (LH), a leading provider of diagnostic laboratory services, maintains a modest dividend profile with a current yield of 1.09%. The company pays a quarterly dividend of $0.72 per share, equating to an annual payout of $2.88. This schedule has been consistent, with the next ex-dividend date set for May 29, 2026, and payment on June 11, 2026. Labcorp is not classified as a high-yield or dividend growth stock but rather a reliable payer with low payout exposure, appealing to those seeking stability in the healthcare diagnostics sector. The dividend policy emphasizes regular quarterly distributions supported by robust operational cash flows.

Dividend History and Growth

Labcorp Holdings has paid dividends consistently on a quarterly basis without interruptions or cuts in recent years. The current $0.72 quarterly rate has held steady, reflecting a flat growth trajectory over the past several years, with zero percent annualized growth recently. Over the past five years, the company raised its dividend twice, though the overall payout has not increased meaningfully. This conservative approach aligns with Labcorp's strategy to balance shareholder returns with reinvestment in growth areas like advanced diagnostics and acquisitions. While lacking a long dividend growth streak, the reliability of payments underscores financial discipline.

Dividend Sustainability and Payout Ratio

The dividend's sustainability is robust, with a payout ratio of 27.5%—well below levels that could strain earnings. This metric, which measures dividends as a percentage of earnings, leaves ample room for reinvestment or potential future increases. Free cash flow coverage is even stronger at around 17%, supported by 2024 FCF of $1.098 billion. Labcorp's balance sheet features manageable debt levels and steady cash generation from its core diagnostics business, further bolstering confidence in ongoing payments amid economic or sector-specific pressures.

Dividend Compared to Industry Peers

Labcorp's 1.09% yield is modest compared to primary peer Quest Diagnostics (DGX), which offers about 1.75% with a higher payout ratio of 36%. Within the broader healthcare diagnostics industry, yields typically range from 1% to 2%, aligning Labcorp below average but with superior coverage metrics. S&P 500 healthcare stocks average around 1.8%. This positions LH as a lower-yielding but safer option relative to peers emphasizing income over growth.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to streamline your research.

Is This Stock Attractive for Dividend Investors?

Labcorp Holdings suits conservative dividend investors who prioritize sustainability and low risk over high yields. Its sub-30% payout ratio and strong FCF coverage make it resilient to healthcare sector volatility, such as reimbursement changes or demand fluctuations. Those building diversified portfolios with stable payers may find LH appealing, particularly alongside growth-oriented holdings. Income-focused investors might prefer higher-yielding peers like DGX, but Labcorp offers peace of mind for long-term holders valuing consistency. The flat growth profile limits appeal for dividend growth enthusiasts seeking annual raises. Overall, it fits balanced strategies emphasizing capital preservation in diagnostics.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations